Nordic digital therapeutics company SidekickHealth has entered into a strategic partnership with Bayer to provide its digital medication management and lifestyle change platform to patients suffering from Peripheral Artery Disease (PAD).
Sidekick develops gamified digital therapeutic (DTx) solutions and programs, designed to transform chronic disease management across multiple therapeutic areas in alliance with key stakeholders in the pharmaceutical and healthcare industries.
PAD is a chronic disease in which plaque builds up in the arteries that carry blood to the suffer’s head, organs, and limbs. If left unchecked, PAD could expose people to acute, even fatal, cardiovascular events.
Sidekick and Bayer have agreed to launch the program in Sweden, with the aim to roll it out across other European markets, collaborating with key opinion leaders and clinical experts in PAD — including the President of the Swedish Society of Vascular Surgery Dr. Carl Wahlgren – at three leading Swedish university hospitals: Karolinska Institutet, Sahlgrenska University Hospital, and Skane University Hospital.
“Lifestyle change is at the heart of what we do, and our programs can have a multiplier effect on the positive outcomes of medical care and the world’s best medicines,” Tryggvi Thorgeirsson, M.D., MPH, Co-Founder and CEO of SidekickHealth, said in a statement. “We reinforce medication adherence and use it as a gateway to bring about positive lifestyle change in a much broader sense. We are excited to be working with Bayer to help patients take that first step and beyond,” Thorgeirsson added.
Sidekick’s clinically-validated digital platform has demonstrated its effectiveness, helping people modify their behavior, increase treatment adherence and better manage chronic illnesses and symptoms. It has been rated in the top 0.1% in quality by the industry’s leading rating company Orcha and is proud of successful customer launches across multiple therapeutic areas — ranging from type 2 diabetes, ulcerative colitis and smoking cessation.
The partnership builds on the previous relationship between the two companies, with Sidekick being accepted Sidekick into the Bayer G4A program.
Earlier this year, Sidekick entered into an agreement with New York-listed Pfizer to develop a DTx smoking cessation solution in partnership with the pharmaceutical giant’s Austrian unit.